Triiodothyronine treatment in mice improves stroke outcome and reduces blood-brain barrier damage.

Application of T3 within 4.5 h of tMCAO, which corresponds to the clinical rtPA time window for intervention in humans, showed a nonsignificant trend to reduction ( P = 0.066) but had no beneficial effects when given at a later time point ( Fig. 1C ).

also in 5,406 other papers